Pfizer Nears Agreement to Buy Medivation

Pfizer Inc (PFE.N) is in advanced talks to acquire U.S. cancer drug company Medivation Inc (MDVN.O) for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday. Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people … Continued

Read More